GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nectar Lifesciences Ltd (LUX:NECLF) » Definitions » Debt-to-Asset

Nectar Lifesciences (LUX:NECLF) Debt-to-Asset : 0.29 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Nectar Lifesciences Debt-to-Asset?

Nectar Lifesciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $59.7 Mil. Nectar Lifesciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $16.9 Mil. Nectar Lifesciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $263.9 Mil. Nectar Lifesciences's debt to asset for the quarter that ended in Mar. 2024 was 0.29.


Nectar Lifesciences Debt-to-Asset Historical Data

The historical data trend for Nectar Lifesciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nectar Lifesciences Debt-to-Asset Chart

Nectar Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.38 0.36 0.34 0.29

Nectar Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 - 0.32 - 0.29

Competitive Comparison of Nectar Lifesciences's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nectar Lifesciences's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Nectar Lifesciences's Debt-to-Asset falls into.



Nectar Lifesciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Nectar Lifesciences's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(59.651 + 16.9) / 263.915
=0.29

Nectar Lifesciences's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(59.651 + 16.9) / 263.915
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nectar Lifesciences  (LUX:NECLF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Nectar Lifesciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Nectar Lifesciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Nectar Lifesciences (LUX:NECLF) Business Description

Traded in Other Exchanges
Address
SCO 38-39, Sector 9d, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products, The company's product includes cefixime trihydrate, cefdinir, cefprozil, cefoxitin sodium, cefpirome sulphate, and others. Geographically, it derives a majority of its revenue from India.

Nectar Lifesciences (LUX:NECLF) Headlines

No Headlines